Valuation: Prescient Therapeutics Limited

Market Cap 64.14M 44.47M 38.85M 35.68M 33.27M 63.08M 4.23B 430M 166M 2.08B 167M 163M 7.15B P/E 2024
-3.71x
P/E 2025 -4.84x
Enterprise Value 57.22M 39.66M 34.66M 31.83M 29.68M 56.27M 3.78B 383M 149M 1.85B 149M 146M 6.38B EV / Sales 2024
4.42x
EV / Sales 2025 6.54x
Free-Float
89.43%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Prescient Therapeutics Limited

1 day+8.06%
1 week+15.52%
Current month+9.84%
1 month-14.10%
3 months+26.42%
6 months-20.24%
Current year-20.24%
1 week 0.06
Extreme 0.06
0.07
1 month 0.06
Extreme 0.057
0.08
Current year 0.05
Extreme 0.049
0.1
1 year 0.04
Extreme 0.04
0.12
3 years 0.04
Extreme 0.037
0.12
5 years 0.04
Extreme 0.037
0.3
10 years 0.02
Extreme 0.022
0.3
Manager TitleAgeSince
Chief Executive Officer 54 2025-01-19
Director of Finance/CFO 53 -
Chief Tech/Sci/R&D Officer - 2025-03-23
Director TitleAgeSince
Chairman - 2025-03-29
Director/Board Member - 2020-05-31
Director/Board Member 71 2023-05-14
Date Insider Type Main position Quantity % Market Cap.
23-05-01Expiration

Chief Executive Officer

2,351,064 0.2926%
23-05-01Fiscal year

Chief Executive Officer

1,148,936 0.1430%
23-04-03Sell

Chairman

17,813 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
+8.06%+15.52%+63.41%-17.28% 44.99M
+0.36%+6.85%+0.11%+5.85% 48.62B
-0.75%+5.17%+403.83%+598.38% 39.86B
+2.93%+11.07%+25.76%-6.34% 33.91B
+1.55%+7.26%+20.88%+63.31% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+34.25%+3.97% - - 16.63B
+2.77%+6.64%+70.07%+131.97% 15.52B
+0.99%+3.16%+13.75%+18.88% 13.63B
-2.14%+7.08%+14.28%-29.08% 13.41B
Average +1.57%+7.60%+69.74%+88.68% 23.87B
Weighted average by Cap. +0.83%+7.73%+87.85%+129.19%

Financials

2024 2025
Net sales 3.71M 2.57M 2.25M 2.07M 1.93M 3.65M 245M 24.86M 9.64M 120M 9.66M 9.45M 414M 4.36M 3.02M 2.64M 2.42M 2.26M 4.28M 288M 29.18M 11.31M 141M 11.34M 11.09M 486M
Net income -8.24M -5.71M -4.99M -4.58M -4.27M -8.1M -544M -55.17M -21.38M -267M -21.44M -20.98M -919M -7.32M -5.08M -4.44M -4.07M -3.8M -7.2M -483M -49.04M -19.01M -237M -19.06M -18.65M -817M
Net Debt -14.18M -9.83M -8.59M -7.89M -7.36M -13.95M -936M -94.99M -36.81M -459M -36.92M -36.11M -1.58B -6.93M -4.8M -4.2M -3.85M -3.59M -6.81M -457M -46.39M -17.98M -224M -18.03M -17.64M -773M
Logo Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company. It is engaged in developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, CellPryme-M, and OmniCAR. PTX-100 is a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. PTX-100 is in a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma with Fast Track Designation. CellPryme-M is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. OmniCAR is a universal CAR platform that is controllable, with plug and play capabilities to enable a wider range of cancers to be targeted. OmniCAR enables controllable T-cell activity and multiantigen targeting with a single cell product.
Employees
3
Date Price Change Volume
26-07-02 A$0.0670 +8.06% 351,979
26-07-01 A$0.0620 +1.64% 272,943
26-06-30 A$0.0610 -3.17% 965,672
26-06-29 A$0.0630 +3.28% 547,265
26-06-26 A$0.0610 -7.58% 2,596,939